- Lobbying
- Lobbying by Exela Holdings, LLC
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Henry Menn III | COS Sen Bob Graham (01-04); Min SD & Counsel, S Vets Cmte 04 CoS, Sen. Bob Graham (2001 - 2004); Min SD & Counsel, Cmte on Vet Affairs (2004); Sp Asst Leg Aff, FDA Office of Commissioner (1993-1995) COS,Sen.Graham (01-04); Min SD&Counsel, Cmte Vet Affairs(04) COS, Sen Graham (01-04);Min SD&Counsel, CmteVet Affairs (04) CoS, Sen. Bob Graham (01 - 04) |
Lisa Layman | SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001 - 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) SPA, Sen. Stabenow (05-07) |
Christopher Bowlin | Hlth & Dom Policy Adv, Sen McCain (09-13) Hlth & Dom Policy Advisor, Sen McCain (09-13) |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Q2 Report
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Registration
Issue(s) they said they’d lobby about: HCR: Issues relating to drug shortage - Public Law No: 112-144, FDA Safety and Innovation Act;
PHA: Issues relating to drug compounding - Public Law 113-54.
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate